• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脂氧素A4作为新型冠状病毒肺炎的潜在预后标志物

LipoxinA4 as a Potential Prognostic Marker of COVID-19.

作者信息

Jamali Farzaneh, Shahrami Bita, Mojtahedzadeh Amirmahdi, Najmeddin Farhad, Arabzadeh Amir Ahmad, Hadadi Azar, Sharifzadeh Mohammad, Mojtahedzadeh Mojtaba

机构信息

Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Semmelweis University, Faculty of Medicine, Budapest, Hungary.

出版信息

J Lipids. 2022 Jul 5;2022:8527305. doi: 10.1155/2022/8527305. eCollection 2022.

DOI:10.1155/2022/8527305
PMID:35812307
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9259546/
Abstract

This pilot study aimed to determine early changes of LXA levels among the hospitalized patients confirmed as COVID-19 cases following the clinical management and its correlation with commonly used inflammatory markers, including erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), and ferritin. Thirty-one adult hospitalized patients infected with the non-severe COVID-19 were included. LXA levels were measured at the baseline and 48-72 hours after hospitalization. Accordingly, ESR and CRP levels were collected on the first day of hospitalization. Moreover, the maximum serum ferritin levels were determined during the five days. LXA levels significantly increased at 48-72 hours compared to the baseline. ESR, CRP, and ferritin levels were positively correlated with the increased LXA4. In contrast, aging was shown to negatively correlate with the increased LXA levels. LXA may be known as a valuable marker to assess the treatment response among non-elderly patients with non-severe COVID-19. Furthermore, LXA could be considered as a potential treatment option under inflammatory conditions. Further studies are necessary to clarify LXA role in COVID-19 pathogenesis, as well as the balance between such pro-resolving mediators and inflammatory parameters.

摘要

这项初步研究旨在确定确诊为新冠肺炎病例的住院患者在临床治疗后LXA水平的早期变化及其与常用炎症标志物的相关性,这些标志物包括红细胞沉降率(ESR)、C反应蛋白(CRP)和铁蛋白。纳入了31名感染非重症新冠肺炎的成年住院患者。在基线期以及住院后48 - 72小时测量LXA水平。相应地,在住院第一天收集ESR和CRP水平。此外,在五天内测定血清铁蛋白的最高水平。与基线相比,LXA水平在48 - 72小时显著升高。ESR、CRP和铁蛋白水平与LXA4的升高呈正相关。相反,年龄与LXA水平的升高呈负相关。LXA可能是评估非重症新冠肺炎非老年患者治疗反应的一个有价值的标志物。此外,在炎症条件下,LXA可被视为一种潜在的治疗选择。有必要进一步研究以阐明LXA在新冠肺炎发病机制中的作用,以及这种促解决介质与炎症参数之间的平衡。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eef2/9259546/2e9708c1c072/JL2022-8527305.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eef2/9259546/2e9708c1c072/JL2022-8527305.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eef2/9259546/2e9708c1c072/JL2022-8527305.001.jpg

相似文献

1
LipoxinA4 as a Potential Prognostic Marker of COVID-19.脂氧素A4作为新型冠状病毒肺炎的潜在预后标志物
J Lipids. 2022 Jul 5;2022:8527305. doi: 10.1155/2022/8527305. eCollection 2022.
2
Lipoxin A4 Is Increased in the Plasma of Preeclamptic Women.子痫前期女性血浆中脂氧素A4水平升高。
Am J Hypertens. 2016 Oct;29(10):1179-85. doi: 10.1093/ajh/hpw053. Epub 2016 May 13.
3
Impaired resolution of inflammation in human chronic heart failure.人类慢性心力衰竭中炎症反应的不消退。
Eur J Clin Invest. 2014 Jun;44(6):527-38. doi: 10.1111/eci.12265. Epub 2014 Apr 22.
4
Clinical characteristics and the risk factors for severe events of elderly coronavirus disease 2019 patients.2019年冠状病毒病老年患者的临床特征及严重事件的危险因素
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 May 28;45(5):542-548. doi: 10.11817/j.issn.1672-7347.2020.200292.
5
Correlation between inflammatory parameters and pituitary-thyroid axis in patients with COVID-19.新型冠状病毒肺炎患者炎症参数与垂体-甲状腺轴的相关性。
Endocrine. 2021 Dec;74(3):455-460. doi: 10.1007/s12020-021-02863-2. Epub 2021 Sep 13.
6
Dynamic changes and clinical significance of LXA in the perioperative period of cardiopulmonary bypass.白三烯A在体外循环围手术期的动态变化及临床意义
Exp Ther Med. 2019 Apr;17(4):3169-3173. doi: 10.3892/etm.2019.7304. Epub 2019 Feb 22.
7
Lipoxin A4 Regulates Lipopolysaccharide-Induced BV2 Microglial Activation and Differentiation via the Notch Signaling Pathway.脂氧素A4通过Notch信号通路调节脂多糖诱导的BV2小胶质细胞激活和分化。
Front Cell Neurosci. 2019 Feb 4;13:19. doi: 10.3389/fncel.2019.00019. eCollection 2019.
8
Correlation of Low Levels of -1 Antitrypsin and Elevation of Neutrophil to Lymphocyte Ratio with Higher Mortality in Severe COVID-19 Patients.重度新冠肺炎患者中低水平的α1抗胰蛋白酶和中性粒细胞与淋巴细胞比值升高与较高死亡率的相关性
Mediators Inflamm. 2021 Apr 28;2021:5555619. doi: 10.1155/2021/5555619. eCollection 2021.
9
Association between serum inflammatory parameters and the disease severity in COVID-19 patients.血清炎症参数与 COVID-19 患者疾病严重程度的关系。
J Clin Lab Anal. 2022 Jan;36(1):e24162. doi: 10.1002/jcla.24162. Epub 2021 Dec 7.
10
Time-Dependent Protective and Pro-Resolving Effects of FPR2 Agonists on Lipopolysaccharide-Exposed Microglia Cells Involve Inhibition of NF-κB and MAPKs Pathways.时间依赖性 FPR2 激动剂对脂多糖暴露的小胶质细胞的保护和促修复作用涉及 NF-κB 和 MAPKs 通路的抑制。
Cells. 2021 Sep 9;10(9):2373. doi: 10.3390/cells10092373.

引用本文的文献

1
Lipoxin A levels correlate with severity in a Spanish COVID-19 cohort: potential use of endogenous pro-resolving mediators as biomarkers.脂氧素A水平与西班牙新冠病毒疾病2019队列中的疾病严重程度相关:内源性促消退介质作为生物标志物的潜在用途
Front Immunol. 2025 Jan 23;15:1509188. doi: 10.3389/fimmu.2024.1509188. eCollection 2024.
2
Oxylipin concentration shift in exhaled breath condensate (EBC) of SARS-CoV-2 infected patients.SARS-CoV-2 感染患者呼出气冷凝物(EBC)中氧化脂浓度变化。
J Breath Res. 2023 Aug 7;17(4). doi: 10.1088/1752-7163/acea3d.

本文引用的文献

1
Role of specialized pro-resolving lipid mediators in pulmonary inflammation diseases: mechanisms and development.特异性促解决脂质介质在肺部炎症性疾病中的作用:机制与发展。
Respir Res. 2021 Jul 14;22(1):204. doi: 10.1186/s12931-021-01792-y.
2
Role of specialized pro-resolving lipid mediators and their receptors in virus infection: a promising therapeutic strategy for SARS-CoV-2 cytokine storm.专门的促解决脂质介质及其受体在病毒感染中的作用:SARS-CoV-2 细胞因子风暴的有前途的治疗策略。
Arch Pharm Res. 2021 Jan;44(1):84-98. doi: 10.1007/s12272-020-01299-y. Epub 2021 Jan 4.
3
Bioactive Lipids in COVID-19-Further Evidence.
COVID-19 相关生物活性脂质:更多证据。
Arch Med Res. 2021 Jan;52(1):107-120. doi: 10.1016/j.arcmed.2020.09.006. Epub 2020 Sep 9.
4
Underlying Vulnerabilities to the Cytokine Storm and Adverse COVID-19 Outcomes in the Aging Immune System.衰老免疫系统中细胞因子风暴和不良 COVID-19 结局的潜在脆弱性。
J Gerontol A Biol Sci Med Sci. 2021 Feb 25;76(3):e13-e18. doi: 10.1093/gerona/glaa209.
5
Aging immunity may exacerbate COVID-19.衰老的免疫系统可能会加剧新冠病毒感染。
Science. 2020 Jul 17;369(6501):256-257. doi: 10.1126/science.abb0762.
6
COVID-19 and the elderly: insights into pathogenesis and clinical decision-making.COVID-19 与老年人:发病机制和临床决策的新视角。
Aging Clin Exp Res. 2020 Aug;32(8):1599-1608. doi: 10.1007/s40520-020-01631-y. Epub 2020 Jun 16.
7
COVID-19 and Crosstalk With the Hallmarks of Aging.COVID-19 与衰老标志的串扰。
J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):e34-e41. doi: 10.1093/gerona/glaa149.
8
Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication.鉴定感染人类冠状病毒的细胞的脂质组特征:对冠状病毒复制时脂质代谢重编程的影响。
Viruses. 2019 Jan 16;11(1):73. doi: 10.3390/v11010073.
9
Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms.21世纪的炎症与感染治疗:解析炎症消退介质及机制带来的新线索
FASEB J. 2017 Apr;31(4):1273-1288. doi: 10.1096/fj.201601222R. Epub 2017 Jan 13.
10
Resolution of Inflammation: What Controls Its Onset?炎症的消退:是什么控制了它的起始?
Front Immunol. 2016 Apr 26;7:160. doi: 10.3389/fimmu.2016.00160. eCollection 2016.